Bright Minds Biosciences Inc.

Biotechnology • Healthcare • New York, NY, United States • DRUG (NCM)

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

647 865 8622 19 Vestry Street, New York, NY 10013, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Why Bright Minds Biosciences Stock Topped the Market on Monday - The Motley Fool

The Motley Fool • Nov 17

H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target - Investing.com

Investing.com • Dec 31

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade - Yahoo Finance

Yahoo Finance • Sep 18

Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% Higher - Here's Why - MarketBeat

MarketBeat • Dec 31

Uncover the Best-Performing Canadian Biotech Stocks of 2025 - Investing News Network

Investing News Network • Dec 30

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has BRIGHT MINDS BIOSCIENCES INC. had layoffs?

No layoff events have been recorded for BRIGHT MINDS BIOSCIENCES INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does BRIGHT MINDS BIOSCIENCES INC. have?

BRIGHT MINDS BIOSCIENCES INC. has approximately 26 employees.

What industry is BRIGHT MINDS BIOSCIENCES INC. in?

BRIGHT MINDS BIOSCIENCES INC. operates in the Biotechnology industry, within the Healthcare sector.

Is BRIGHT MINDS BIOSCIENCES INC. a publicly traded company?

Yes, BRIGHT MINDS BIOSCIENCES INC. is publicly traded under the ticker symbol DRUG on the NCM. The company has a market capitalization of approximately $0.64 billion.

Where is BRIGHT MINDS BIOSCIENCES INC. headquartered?

BRIGHT MINDS BIOSCIENCES INC. is headquartered in New York, NY, United States at 19 Vestry Street, New York, NY 10013, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.